Business Wire

New Subgroup Analysis of the Phase 3 OPTIMUM Study Demonstrates the Benefits of PONVORY TM ▼ (ponesimod) Over teriflunomide in Early Disease Multiple Sclerosis

Share

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from a new subgroup analysis of the pivotal Phase 3 OPTIMUM trial. Featured as an e-poster at the 37th Congress of the European Committee for Treatment Research in Multiple Sclerosis (ECTRIMS) from October 13-15, the subgroup analysis showed that in the expanded disability status scale (EDSS) ≤ 3 subgroup, ponesimod significantly reduced annualised relapse rate (ARR) by 47 percent (rate ratio [RR] = 0.53; 99 percent confidence levels [CLs]: 0.372, 0.755; p<0.0001) and MS-fatigue was statistically significantly lower in the ponesimod group compared with the teriflunomide group at week 108, with a mean difference (MD) of -4.31 (95 percent CLs: -6.99, -1.63; p=0.0017).1,2

“Multiple sclerosis is a debilitating and degenerative disease for which there is no cure, so our current focus is on preventing progression and minimising relapses,” said Allitia DiBernardo, M.D., lead author of the e-poster and Global Medical Affairs Head, Neurology, Janssen Global Services, LLC. “The OPTIMUM subgroup analysis supports the principle of early treatment intervention with high potency therapies such as ponesimod, which aims to reduce relapse rates, improve patient outcomes and ultimately contribute to a better quality of life for people living with MS.”

The OPTIMUM study subgroup analysis randomised 1,133 patients (ponesimod, n = 567; teriflunomide, n = 566) and examined those with EDSS ≤ 3 (up to moderate disability in one function, or mild disability in 3 or 4 functions; no impairment to walking) and/or who were treatment naïve.1

The analysis showed that in treatment-naïve patients, ponesimod significantly reduced ARR (RR = 0.714; 99 percent CLs: 0.486, 1.049; p=0.0241) and MS-fatigue was significantly lower in the ponesimod group compared with the teriflunomide group at week 108, MD = -5.30 (95 percent CLs: -8.25, -2.35; p=0.0004).1,2

Results from this subgroup analysis for combined unique active lesions (CUALs) were consistent with the overall population. Patients significantly benefited from ponesimod compared with teriflunomide in both the EDSS ≤3 (RR = 0.424; 95 percent CLs: 0.329, 0.546; p<0.0001) and treatment-naïve (RR = 0.411; 95 percent CLs: 0.310, 0.545; p<0.0001) groups.1,2

“These data represent a significant contribution towards our goal of making a positive impact for people living with MS,” said Tamara Werner-Kiechle, M.D., Therapeutic Area Lead Neuroscience & Pulmonary Hypertension, Europe, Middle East and Africa (EMEA), Janssen Cilag GmBH. “The further research on ponesimod is testimony to our commitment to support people living with MS, with a particular focus on improving the treatment landscape in relapsing MS, where medical unmet needs among the MS community remain.”

#ENDS#

About Multiple Sclerosis
MS is a chronic autoimmune inflammatory disease of the central nervous system (CNS) in which immune cells attack myelin (the protective casing that insulates nerve cells), damaging or destroying it and causing inflammation.3 This affects how the CNS processes information and communicates with the rest of the body, causing the neurologic signs and symptoms of MS.4 Symptoms vary by person, but common symptoms include fatigue, balance and walking problems, numbness or tingling, dizziness and vertigo, vision problems, bladder and bowel problems and weakness.4,5,6

About PONVORYTM(ponesimod)
Ponesimod is a daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, indicated for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease defined by clinical or imaging features.7,8 Ponesimod is believed to work by keeping immune cells called lymphocytes out of the blood by trapping them in the lymph nodesand out of the central nervous system, where they could cause damage.8

Ponesimod does not require genetic testing or first-dose cardiac monitoring for most patients. Because initiation of ponesimod treatment results in a decrease in heart rate, first-dose monitoring is recommended in patients with certain pre-existing cardiac conditions.8

It is not known if ponesimod is safe and effective in children.

On 19 May 2021, the European Commission approved ponesimod for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.8,9

A member of the Janssen Pharmaceutical Companies of Johnson & Johnson, Actelion Pharmaceuticals Ltd is party to a revenue sharing agreement with Idorsia Pharmaceuticals Ltd, which provides for certain payments to Idorsia related to the sales of ponesimod.

About the OPTIMUM trial
The Phase 3 OPTIMUM (NCT02425644) trial – a large pivotal trial and the first to compare an oral disease-modifying therapy (DMT) vs. another oral DMT – was a multicentre, randomised, double-blind, parallel-group, active-controlled superiority study. The trial was designed to evaluate the efficacy and safety of once daily oral ponesimod 20mg vs. once per day teriflunomide 14mg, an approved and widely-used first-line oral treatment, in adult patients with RMS. In total, 1,133 adult patients were randomised at 162 sites in 28 countries.10

The primary endpoint of the 108-week study was the ARR (ponesimod showed a statistically significant rate reduction of 30.5 percent. The ARR for ponesimod 20mg was 0.202 vs. 0.290 for teriflunomide 14mg [p=0.0003]). Secondary endpoints included CUAL per year on magnetic resonance imaging (MRI) to week 108 (ponesimod significantly reduced the number of new inflammatory lesions on brain MRI by 56 percent [p<0.0001] at week 108 when compared to teriflunomide) and time to 12- and 24-week confirmed disability accumulation to end of study (ponesimod-treated patients also showed a numerical benefit in delaying disability progression compared to teriflunomide-treated patients, and had small improvements in the risk of new 3- and 6-month disability [17 percent and 16 percent lower risk, respectively, compared to teriflunomide], although the between-group difference was not statistically significant in either instance).10

The safety profile of ponesimod is consistent with the known safety profile of other S1P receptor modulators, although a head-to-head comparison, other than with teriflunomide, is not available. Overall, the number of treatment-emergent adverse events reported was similar between the ponesimod and teriflunomide treated groups, and the majority were mild/moderate and did not warrant treatment discontinuation. The most frequently reported adverse events in the ponesimod 20mg group vs. the teriflunomide 14mg group were Alanine Aminotransferase (ALT) enzyme elevations (19.5 percent vs. 9.4 percent), nasopharyngitis (19.3 percent vs. 16.8 percent), headache (11.5 percent vs. 12.7 percent), upper respiratory tract infection (10.6 percent vs. 10.4 percent) and alopecia (3.2 percent vs. 12.7 percent).10

Adverse events should be reported. This medicinal product is subject to additional monitoring and it is therefore important to report any suspected adverse events related to this medicinal product.

About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Learn more at www.janssen.com/emea. Follow us at www.twitter.com/janssenEMEA for our latest news.

Janssen-Cilag International NV, the marketing authorisation holder for PONVORY™ (ponesimod) in the EU, Janssen Global Services, LLC, and Janssen Cilag GmBH are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding ponesimod. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Janssen-Cilag International NV, Actelion Pharmaceuticals Ltd, Janssen Pharmaceutica NV and/or any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

###

References

  1. DiBernardo A, Turkoz I et al. Ponesimod demonstrated increased clinical benefit over teriflunomide in early disease subgroup compared with overall population. E-poster at the Congress of the European Committee for Treatment Research in Multiple Sclerosis (ECTRIMS) 13-15 October 2021.
  2. DiBernardo A, Turkoz I et al. Ponesimod demonstrated increased clinical benefit over teriflunomide in early disease subgroup compared with overall population. Abstract at the Congress of the European Committee for Treatment Research in Multiple Sclerosis (ECTRIMS) 13-15 October 2021.
  3. National Multiple Sclerosis Society. Definition of MS. Available at: https://www.nationalmssociety.org/What-is-MS/Definition-of-MS. Last accessed: October 2021.
  4. National Multiple Sclerosis Society. Symptoms and Diagnosis. Available at: https://www.nationalmssociety.org/Symptoms-Diagnosis. Last accessed: October 2021.
  5. Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016;9(1):5-48.
  6. National Multiple Sclerosis Society. Cognitive Changes. Available at: https://www.nationalmssociety.org/Symptoms-Diagnosis/MSSymptoms/Cognitive-Changes Last accessed: October 2021.
  7. D'Ambrosio D, Freedman MS, Prinz J. Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases. Ther Adv Chronic Dis. 2016;7(1):18-33. doi:10.1177/2040622315617354.
  8. Ponvory summary of product characteristics, June 2021. Available at: https://www.ema.europa.eu/en/documents/product-information/ponvory-epar-product-information_en.pdf Last accessed: October 2021.
  9. Johnson & Johnson. European Commission approves PONVORYTM(ponesimod), a Once Daily, Oral Therapy for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features. Available at:https://www.janssen.com/emea/sites/www_janssen_com_emea/files/european_commission_approves_ponvorytm_ponesimod_a_once_daily_oral_therapy_for_the_treatment_of_adults_with_relapsing_forms_of_multiple_sclerosis_with_active_disease_defined_by_clinical_or_imaging_features.pdf. Last accessed: October 2021.
  10. Kappos L, Fox RJ, Burcklen M, et al. Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a Randomized clinical trial. JAMA Neurol. 2021.

CP-266001

Date prepared: October 2021

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Enquiries:
Alexandra Nisipeanu
Mobile: +40-74-438-3413
Email: adridean@its.jnj.com

Investor Relations:
Jennifer McIntyre
Office: +1-732-524-3922

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF Names Dennis Maroney Master Perfumer30.11.2022 22:20:00 CET | Press release

IFF (NYSE: IFF) has named Dennis Maroney Master Perfumer, an honor recognizing his career achievements, entrepreneurial contributions and record of commercial excellence in the global perfumery industry. Maroney is a 32-year industry veteran and IFF’s ninth Master Perfumer, a distinction reserved for those who have demonstrated exceptional leadership and measurable impact in perfumery. “Dennis has demonstrated a unique ability to bring together science and creativity, with a strong, undefeatable sense of purpose,” said Frank Clyburn, CEO, IFF. “He is a humble leader and an inspiring mentor who has created milestone scent signatures in the beauty and home care world. His unique contributions to the products we use every day in our beauty and home care routines are truly inspiring, and this Master Perfumer recognition is more than deserved.” Commenting on his Master Perfumer appointment, Maroney said: “Perfumery is about transporting the consumer to a time and place where they are happy.

Digital Integrator Cohesive Group Acquires Vetasi, Leading Provider of IBM Maximo Managed Services30.11.2022 22:03:00 CET | Press release

Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced that its Cohesive Group digital integrator business has acquired Vetasi, a leading international consultancy specializing in enterprise asset management (EAM) solutions, with a strong focus on IBM Maximo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221130006068/en/ Image courtesy - Getty Images Vetasi brings to Cohesive the largest IBM Maximo consultancy team across Europe, Africa, and ASEAN countries, with headquarters in the United Kingdom and operations based in Poland, Indonesia, South Africa, Spain, Ukraine, and Australia. In addition to EAM resources, Vetasi deepens the Cohesive team with additional strategic advisory capabilities and adds to the Cohesive services catalog Maximo cloud hosting capabilities, expertise in low-code development, and strong real estate and facilities management domain knowledge. B

Everest Group Recognizes SoftServe as a Key Player in Digital Services within the Life Sciences Landscape30.11.2022 18:47:00 CET | Press release

SoftServe, a leader in digital services and consulting, has been recognized as an Aspirant in Everest Group's Life Sciences Digital Services PEAK Matrix® Assessment 2022. Everest Group is a provider of strategic research insights on IT, business processes, and engineering services and a global Business Process Outsourcing (BPO) research firm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221130005890/en/ Everest Group Recognizes SoftServe as a Key Player in Digital Services within the Life Sciences Landscape (Graphic: Business Wire) The Life Sciences Digital Services PEAK Matrix® Assessment 2022 covers the top digital life sciences service providers, best-in-class solutions and products, and top locations, according to Everest Group's research. This is the first time SoftServe has been named in the Life Sciences sector. SoftServe debuted with an impressive score in Everest Group's two assessment areas: vision and strategy a

Leading Payments Innovator Chooses Verimatrix XTD Technology to Bolster Cybersecurity30.11.2022 17:45:00 CET | Press release

Regulatory News: Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that Norway-based Tidypay, a provider of enterprise-level payment solutions that are flexible enough for businesses of all sizes, selected Verimatrix Extended Threat Defense (XTD) technologies to protect and monitor the apps that power its solutions. A top European payment services provider that aims to greatly simplify the payment journey, Tidypay looked to Verimatrix XTD to strengthen security for its Tidypay One, Tidypay eCom and Tidypay GO solutions that serve as the backbones of its many services, including integrated POS systems, accounting systems and individual mobile standalone devices. Through Verimatrix XTD, the company, its partners and users benefit from proven defenses against application repackaging, debuggers, dynamic modification, emulators, reverse engineering, and more. “Verimatrix shares our vision of efficiency and sim

IWBI Launches the WELL Equity Rating to Advance Organizations and Places Where “Everyone Feels Welcome, Seen and Heard”30.11.2022 17:27:00 CET | Press release

The International WELL Building Institute (IWBI) announced today the launch of the WELL Equity Rating, a new rating designed to help organizations act on their diversity, equity, inclusion and accessibility goals, and improve company culture and employee health. Over 30 leading organizations – including AvalonBay Communities, Canderel, Empire State Realty Trust, JLL, Overbury, Shaw Industries and the State University of New York (SUNY) College of Environmental Science and Forestry – have already enrolled in the rating, demonstrating their commitment to creating places where everyone has an equalopportunity to thrive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221130005749/en/ (Graphic: Business Wire) By providing an evidence-based roadmap, the WELL Equity Rating empowers organizations to better address the needs of marginalized and underserved populations and take an action-oriented approach to creating equitable, people

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom